Literature DB >> 29914023

Amyloid-Mediated Cholinergic Dysfunction in Motor Impairment Related to Alzheimer's Disease.

Tommaso Schirinzi1, Francesco Di Lorenzo1, Giulia Maria Sancesario2,3, Giulia Di Lazzaro1, Viviana Ponzo3, Antonio Pisani1,3, Nicola Biagio Mercuri1,3, Giacomo Koch3, Alessandro Martorana1.   

Abstract

BACKGROUND: Although motor disturbances parallel the course of dementia, worsening both quality of life and social costs, the pathogenesis remains still unclear.
OBJECTIVE: Through the combination of cerebrospinal fluid (CSF) biomarkers assessment and transcranial magnetic stimulation (TMS) protocols, here we provided a cross-sectional study to understand pathogenic mechanisms of Alzheimer's disease (AD)-related early motor disturbances.
METHODS: The motor phenotype, as defined with Unified Parkinson's Disease Rating Scale (UPDRS) part 2-3, Rating Scale for Gait Evaluation in Cognitive Deterioration (RSEGCD) and Tinetti scale, together with CSF profile of amyloid-β 42 (Aβ42), total-tau, and phosphorylated-tau were determined in 37 AD patients and compared to 18 patients with vascular dementia (VaD). A TMS protocol of short afferent inhibition (SAI) was further applied on a subset of AD patients. Clinical, biochemical, and neurophysiological data were then compared and correlated in order to find significant associations.
RESULTS: AD patients exhibited subtle locomotor impairment and slight extrapyramidal signs. Main motor features (UPDRS part 3, RSGECD, and Tinetti scale scores) correlate with Aβ42 levels but not with t-tau and p-tau. AD patients also presented SAI impairment directly related to UPDRS part 3 score and Aβ42 levels. Motor disturbances of VaD group did not differ statistically from AD and did not correlate with CSF biomarkers.
CONCLUSIONS: The association of motor disturbances with low Aβ42 CSF levels and individual SAI suggests that amyloid-mediated degeneration of cholinergic system may account for early AD-related motor impairment, providing interesting insights either for frailty stratification of patients or personalized therapies.

Entities:  

Keywords:  Alzheimer’s disease; amyloid; cholinergic; frailty; gait; locomotor; vascular dementia

Mesh:

Substances:

Year:  2018        PMID: 29914023     DOI: 10.3233/JAD-171166

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  14 in total

1.  Association between physical activity and dementia's risk factors in patients with Parkinson's disease.

Authors:  Mohammad Alwardat; Tommaso Schirinzi; Giulia Di Lazzaro; Giulia Maria Sancesario; Donatella Franco; Paola Imbriani; Paola Sinibaldi Salimei; Sergio Bernardini; Nicola Biagio Mercuri; Antonio Pisani
Journal:  J Neural Transm (Vienna)       Date:  2019-02-12       Impact factor: 3.575

2.  Interactions between Soluble Species of β-Amyloid and α-Synuclein Promote Oligomerization while Inhibiting Fibrillization.

Authors:  Jason Candreva; Edward Chau; Margaret E Rice; Jin Ryoun Kim
Journal:  Biochemistry       Date:  2019-12-30       Impact factor: 3.162

Review 3.  The Key Role of Magnetic Resonance Imaging in the Detection of Neurodegenerative Diseases-Associated Biomarkers: A Review.

Authors:  Ke-Ru Li; An-Guo Wu; Yong Tang; Xiao-Peng He; Chong-Lin Yu; Jian-Ming Wu; Guang-Qiang Hu; Lu Yu
Journal:  Mol Neurobiol       Date:  2022-07-12       Impact factor: 5.682

Review 4.  Diagnosis of neurodegenerative dementia: where do we stand, now?

Authors:  Giulia M Sancesario; Sergio Bernardini
Journal:  Ann Transl Med       Date:  2018-09

5.  Ginsenoside Rg1 reduces β‑amyloid levels by inhibiting CDΚ5‑induced PPARγ phosphorylation in a neuron model of Alzheimer's disease.

Authors:  Qiankun Quan; Xi Li; Jianjun Feng; Jixing Hou; Ming Li; Bingwei Zhang
Journal:  Mol Med Rep       Date:  2020-08-07       Impact factor: 2.952

6.  Pre-Existing Disability and Its Risk of Fragility Hip Fracture in Older Adults.

Authors:  Jayeun Kim; Soong-Nang Jang; Jae-Young Lim
Journal:  Int J Environ Res Public Health       Date:  2019-04-07       Impact factor: 3.390

7.  Cholinergic transmission is impaired in patients with idiopathic normal-pressure hydrocephalus: a TMS study.

Authors:  Raffaele Nardone; Stefan Golaszewski; Kerstin Schwenker; Francesco Brigo; Miriam Maccarrone; Viviana Versace; Luca Sebastianelli; Leopold Saltuari; Yvonne Höller
Journal:  J Neural Transm (Vienna)       Date:  2019-06-21       Impact factor: 3.575

8.  Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia.

Authors:  Esther S Oh; Kaj Blennow; George E Bigelow; Sharon K Inouye; Edward R Marcantonio; Karin J Neufeld; Paul B Rosenberg; Juan C Troncoso; Nae-Yuh Wang; Henrik Zetterberg; Frederick E Sieber; Constantine G Lyketsos
Journal:  PLoS One       Date:  2018-09-25       Impact factor: 3.240

9.  Longitudinal Cognitive Decline in a Novel Rodent Model of Cerebral Amyloid Angiopathy Type-1.

Authors:  Dominique L Popescu; William E Van Nostrand; John K Robinson
Journal:  Int J Mol Sci       Date:  2020-03-28       Impact factor: 5.923

10.  One-year outcome of coenzyme Q10 supplementation in ADCK3 ataxia (ARCA2).

Authors:  Tommaso Schirinzi; Martina Favetta; Alberto Romano; Andrea Sancesario; Susanna Summa; Silvia Minosse; Ginevra Zanni; Enrico Castelli; Enrico Bertini; Maurizio Petrarca; Gessica Vasco
Journal:  Cerebellum Ataxias       Date:  2019-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.